AzTrials
AzTrials

Vestibular SchwannomaSPEEDNCT03520829

Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery

An observational study of Vestibular Schwannoma and Brain Metastases, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The process of developing Gamma Knife radiosurgery treatment plans is today very dependent on the level of human expertise resulting in a great heterogeneity of the intrinsic qualities of the treatment planning and the quality of care delivered in radiosurgery. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Intuitive Plan
Type of treatment
Medical device
How many people
30 participants
Where
1 siteFrance
Study dates
10 Jan 2018to 10 Jan 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Single-session treated patient with vestibular schwannoma or multiple brain metastases (> 5) or para-optic meningioma

Who may be able to join

  • Male or female at least 18 years old
  • Patient treated for Gamma Knife
  • Patient who has benefited or needs Gamma-Knife radiosurgical treatment
  • Patient affiliated to a social protection scheme.
  • Patient having understood the information notice and expressed his non opposition.

Who cannot join

  • Patient with a contraindication to perform a brain MRI
  • Patient with a contraindication to radiosurgical treatment (previous treatment with cerebral radiotherapy)
  • Pregnant and lactating women
  • Simultaneous participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
  • Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults unable to express their consent.
  • Patient expressing opposition to participation in the study

Trial locations and contacts

1 site in 1 country.

Jean-Marie REGIS, PU-PH contact

4.91.38.70.59 ext. +33

jeanmarie.regis@ap-hm.fr

France1 site, 1 recruiting
  • Assistance Publique Hôpitaux de Marseille

    Marseille, 13354

    Jean-Marie REGIS, PU-PH, 4.91.38.70.59 ext. +33, jeanmarie.regis@ap-hm.fr

    jean-Marie REGIS, PU-PH

    Recruiting

Other trials in France

About this study

The process of developing Gamma Knife radiosurgery treatment plans is today very dependent on the level of human expertise resulting in a great heterogeneity of the intrinsic qualities of the treatment planning and the quality of care delivered in radiosurgery.

The existing reverse planning systems, although they have progressed considerably in recent years, produce results that are still lower than those achieved by an expert.

Read more

Conventionally, an experienced dosimetric planner will act mainly on the coordinates of the position of the isocenters, on the size of the collimators, sector by sector, and on the irradiation time of each isocenters. In theory, the combination of these variables provides access to billions of combinatorics whose diversity far exceeds the computational capabilities of the human mind. The dosimetric planner therefore uses a very small part of the spectrum of possible patterns by always reproducing a limited number of empirical solutions.

The company Intuitive Therapeutics has developed a new mathematical algorithm which can automatically test in a very short time all the combinatorial possibilities and converge very quickly to the solution that best meets the clinical, anatomical and dosimetric objectives defined by the neurosurgeon. The quick processing of the system also allows the operator to modify the constraints to refine the proposed result in real time.

The demonstration of the reality of the performances of this algorithm would give the ability to even inexperienced users to develop high performance planning for the benefit of the patient in terms of optimizing the efficacy / toxicity ratio of the radiosurgery treatment results

The primary objective is to evaluate comparatively the quality of the schedules produced by the algorithm developed by the company Innovative Therapeutics to those produced by an expert who carried out more than 15000 dosimetric plannings and radiosurgical interventions.

The main criterion of comparison is the Paddick index.

The secondary criteria for comparison are:

  • Compliance index
  • selectivity index
  • Gradient index
  • Maximum, minimum, average dose at risk structures
  • Dose distribution in the target volume
  • Treatment time (at equal source activity)
  • Time of realization of the planning

It was chosen to treat patients with vestibular Schwannoma OR multiple brain metastases (> 5) treated in single session by Gamma Knife OR para-optic meningioma in hypo-fractionated treatment on Gamma Knife with restraint mask with inclusion of visual paths in the target volume planning.

The aim of the study is to show at least the non-inferiority of this new method compared to the expert user based on the Paddick Index. This index has continuous values between 0 and 1, 0 being the worst case and 1 being the ideal solution. In order to define the sample size needed for each pathology, a pilot phase is required. This phase can be performed retrospectively using treatments already defined by the expert user. This pilot phase will allow us to identify the difference that can be expected between the index values and the variability of this difference. Based on these values we will be able to determine the size of the sample allowing us to statistically test the non-inferiority, or even the superiority of this new device. The number of cases to be included during the pilot phase should be at least ten cases and a maximum of thirty cases. The choice of the number of cases to be integrated during this pilot phase will depend on the homogeneity of the differences obtained on the first cases. These values will allow us to calculate the size of the samples necessary for the study of non-inferiority as well as for the study of superiority. Depending on the calculated sizes samples we will make a choice to ensure that this study takes place in the expected duration.

Being tested
Intuitive Plan
Medical subject headings
Neuroma, Acoustic, Brain Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intuitive PlanDevice

    dosimetric planning software

Study groups in NCT03520829
Study groupRoleWhat they receive
Patient treated for Gamma KnifeNot described
Receives: Device: Intuitive Plan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate comparatively the quality of the schedules produced by the algorithm developed

    to show at least the non-inferiority of this new method compared to the expert user based on the Paddick Index. This index has continuous values between 0 and 1, 0 being the worst case and 1 being the ideal solution

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2018
  2. Study start10 Jan 2018
  3. Primary completion10 Jan 2019 (estimated)
  4. Study completion10 Jan 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03520829
Sponsor's protocol ID
2017-52
Other IDs
2017-A02753-50
Acronym
SPEED
Status last verified
Apr 2018
First submitted
27 Apr 2018
Last updated
17 May 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Vestibular Schwannoma and Brain Metastases, run by Assistance Publique Hopitaux De Marseille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 May 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jean-Marie REGIS, PU-PH (4.91.38.70.59 ext. +33, jeanmarie.regis@ap-hm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate comparatively the quality of the schedules produced by the algorithm developed (time frame: one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in